Although these findings suggest an insulin-independent, direct anti-tumoral activity for metformin, it remains unknown whether cancer cell-autonomous alterations that are known to drive insulin/IGF-1-independent, DR-resistant tumors preclude the anti-cancer activity of metformin. Here, INS is linked to cancer.